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Simple Summary: Colorectal cancer (CRC) is one of the leading causes of cancer mortality; it typically
originates as adenomas that progress over time to carcinomas. We decided to investigate the
accumulation of numerous genomic alterations during tumour progression by using a mouse model
with three different targetable alleles that can be found in human colorectal cancers. We conclude
that the rate of accumulation of SNSs is higher in transformed compared to non-transformed cells,
and that it is unaffected by the number of cancer-driver genes that are active in the tumour.
Abstract: The genomes of many human CRCs have been sequenced, revealing a large number of
genetic alterations. However, the molecular mechanisms underlying the accumulation of these
alterations are still being debated. In this study, we examined colorectal tumours that developed in
mice with Apclox/lox, LSL-KrasG12D, and Tp53lox/lox targetable alleles. Organoids were derived from
single cells and the spectrum of mutations was determined by exome sequencing. The number of
single nucleotide substitutions (SNSs) correlated with the age of the tumour, but was unaffected by
the number of targeted cancer-driver genes. Thus, tumours that expressed mutant Apc, Kras, and
Tp53 alleles had as many SNSs as tumours that expressed only mutant Apc. In contrast, the presence
of large-scale (>10 Mb) copy number alterations (CNAs) correlated strongly with Tp53 inactivation.
Comparison of the SNSs and CNAs present in organoids derived from the same tumour revealed
intratumoural heterogeneity consistent with genomic lesions accumulating at significantly higher
rates in tumour cells compared to normal cells. The rate of acquisition of SNSs increased from
the early stages of cancer development, whereas large-scale CNAs accumulated later, after Tp53
inactivation. Thus, a significant fraction of the genomic instability present in cancer cells cannot be
explained by aging processes occurring in normal cells before oncogenic transformation.
Keywords: colorectal cancer; single cell; genomic instability; exome sequencing; mouse models;
cancer drivers; single nucleotide variants; copy number alterations; mutational signature; organoids
1. Introduction
The colon is an excellent organ for studying the accumulation of genomic alterations
during cancer development because precancerous and cancerous lesions can be easily
harvested [1–6]. The initial event in most colorectal carcinomas (CRCs) is biallelic inactiva-
tion of the tumour-suppressor gene Adenomatous polyposis coli (APC) [2,7–9]. Further CRC
development involves the accumulation of additional mutations that may be subclone-
specific [6,10–15]. Activating mutations targeting KRAS are acquired in up to 40–50%
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of sporadic CRCs and are associated with dysplasia [2,8,16]. Up to 50–60% of human
CRCs acquire inactivating mutations in the TP53 tumour-suppressor gene, an event as-
sociated with progression of dysplastic lesions to carcinoma. p53, the protein product
of TP53, induces cell cycle arrest, senescence, or apoptosis in response to DNA damage.
Thus, its inactivation allows cancer cells to survive and proliferate despite the presence of
oncogene-induced DNA damage [17].
Identification of the genes that are frequently mutated in human CRC allowed mouse
models to be generated. The first model to be generated harboured a deletion in one
allele of the Apc gene (Apcmin/+) [18]. Although this model has been studied extensively,
it does not fully recapitulate human CRC because the tumours develop mainly in the small
intestine and they are benign adenomas [18,19]. Another mouse model has mutations in
both the Apc and Kras genes; these mice show higher tumour multiplicity than Apcmin
mice and more importantly the colonic tumours invade the intestinal mucosa [16,20,21].
As TP53 inactivating mutations are frequent in advanced human CRC, yet another mouse
model was generated by combining mutations in the Apc, Kras and Tp53 genes (AKP
model). In these mice, aggressive carcinomas develop in the ceacum and colon [22,23].
Moreover, cell lines established from these tumours are able to metastasise to the liver after
intrasplenic injection or orthotopic transplantation into immunodeficient mice [22,24].
One of the most important hallmarks of cancer, including CRC, is genomic instability,
a feature that facilitates cancer progression [25] and resistance to therapy [11,26,27]. Ge-
nomic instability can lead to the accumulation of numerous genomic alterations, including
single nucleotide substitutions (SNSs), small insertions and deletions (indels), copy number
alterations (CNAs), and chromosomal rearrangements. It is well established that CNAs
and chromosomal rearrangements accumulate at higher rates in cancer cells than in normal
cells. However, it is less clear whether the rate of acquisition of SNSs increases after cell
transformation. The early consensus in the field has been that the high number of SNSs in
most human cancers simply reflect the high number of point mutations present in normal
cells due to aging; since tumours are of monoclonal origin, these mutations become evident
when tumour DNA is sequenced [28]. An alternative view is that SNSs accumulate at
higher rates in cancer cells. Our sequencing study of human colon adenomas supported this
latter view, since it revealed a higher number of SNSs in adenomas with severe dysplasia,
compared to adenomas with mild dysplasia, despite similar patient age distribution [29].
One may also consider the possibility that certain types of mutations accumulate at higher
rates in cancer cells, whereas other types of mutations accumulate at equal rates in normal
and cancer cells due to, for example, aging. Along these lines, it is worth noting that the
large-scale sequencing studies of human cancers have revealed distinct types of SNSs that
are referred to as mutational signatures [30–33]. Various bulk tissue sequencing studies
of genetically engineered mouse models (GEMMs), that recapitulate aspects of human
cancers have also revealed a spectrum of SNSs [33–40].
The prevailing signature in human cancers is signature 1, a signature that is defined
by a high number of C-to-T transitions in the context of CpG sites [32,41]. These mutations
arise from failure to properly repair a methylated cytosine, after it has been deaminated by
hydrolysis [42]. It has been proposed that signature 1 mutations accumulate with equal
rates in normal and cancer cells [43–45]. However, the majority of mutations in colon
cancer conform to signature 1 and our exome sequencing study, cited above, revealed a
higher number of signature 1 SNSs in adenomas with severe dysplasia, compared to mild
dysplasia. A higher mutation rate for signature 1 SNSs can be rationalised on the basis that
cancer cells have DNA replication stress, which leads to the formation of single-stranded
DNA [17]. The rate of cytosine deamination is a hundred times higher in single-stranded
than in double-stranded DNA [42], and deamination of a methylated cytosine to thymine
in single-stranded DNA cannot be detected by the repair machinery because it does not
lead to base pair mismatches and because thymine is a naturally occurring base in DNA.
Understandably, interpretation of cancer sequencing data is complicated by the pres-
ence of intratumoural heterogeneity [28,46]. Mutations that are present in a subset of
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cancer cells may have very low overall allele frequencies and not be counted. To address
this problem, one can prepare single cell-derived tumour organoids for sequencing. In a
previous study, we sequenced the exomes of organoids derived from normal or precan-
cerous single cells isolated from the intestines of Apcmin/+ mice and observed eleven times
more mutations in the organoids derived from the precancerous cells [47]. Another study
also examined single cell-derived organoids; in this latter study, organoids were prepared
from cancer and normal cells obtained from three CRC human patients. Comparison of
the number of mutations in the tumour-derived organoids, as compared to the normal
tissue-derived organoids, revealed a modest increase in the number of SNSs conform-
ing to signature 1 and a more significant increase in the number of SNSs conforming to
signature 17 [48].
To gain a better understanding of mutation rates in cancer cells, we turned to a mouse
model of CRC that is driven by three cancer driver genes. Specifically, we examined mice
that had three targetable alleles: Apclox/lox, LSL-KrasG12D, and Tp53lox/lox, corresponding to
the most frequently mutated genes in human colon cancer [49,50]. The mice also harboured
a transgene that was expressed specifically in the colon and which encoded a tamoxifen-
inducible recombinase (Cdx2CreERT2), allowing the three cancer-driver genes to be targeted
in an inducible manner. As before, we prepared single cell-derived organoids from CRCs
that developed in these mice and sequenced their exomes. Our results provide a better
understanding of the role of oncogenes and tumour suppressor genes on the accumulation
of SNSs and CNAs in cancer cells.
2. Results
2.1. Clonal Organoid Cultures Derived from Single Tumoral Cells
We used a mouse model of colonic tumorigenesis (AKP-Cdx2CreERT2 mice), in which
three endogenous cancer-driver genes were modified, so they could be targeted by a
tamoxifen-inducible Cre gene. The targeted cancer-driver genes were Apc, whose exon
15 was flanked by loxP sites (Apclox/lox), Kras, which contained a G12D mutation and a
transcription termination site flanked by loxP sites upstream of the first coding exon
(KrasLSL-G12D/+), and Tp53, whose exons 2–10 were flanked by loxP sites (Tp53lox/lox)
(Figure 1a and Figure S1a). The Cre gene was under control of the Cdx2 promoter to
confer specific expression in the large intestine.
We administered tamoxifen to four mice (Figure 1b). The first mouse (mI) received a
dose of 30 mg/kg, which led to multiple transformation events across the whole caecum;
this mouse was sacrificed two weeks after tamoxifen administration. The other three mice
received a low tamoxifen dose of 3 mg/kg, which led to low levels of recombination and
few tumours developing. Mouse II was sacrificed ten weeks after tamoxifen injection. Mice
III and IV were sacrificed 20 and 25 weeks after tamoxifen injection, respectively. These
mice developed carcinomas, which invaded the bowel wall and reached the peritoneum
(Figure S1c). Tissue biopsies with macroscopically visible tumours were used to prepare
suspensions of single cells, which were then aliquoted into wells of 96-well plates for
expansion as 3D-organoid cultures (Figure 1c and Figure S1b). We only propagated
cultures from wells, in which initially only a single organoid grew, and we considered
that these cultures were derived from a single cell. The organoids were spheroid-shaped
and lacked the crypt-like projections that are typical of intestinal organoids derived from
non-transformed cells (Figure S1b).
A diagnostic PCR, supported by analysis of the number of exome sequencing reads,
was used to determine whether the Apc, KrasG12D, and Tp53 genes had undergone recombi-
nation by Cre (Figure 1d). As expected, all tumour-derived organoids retained the Cre gene
(Figures S2a and S11) and had suffered biallelic deletions of exon 15 of Apc (Figures S2b, S3
and S11). The KrasG12D allele had also recombined in all organoids (Figure 1d; Figures S2c,
S4, S5 and S11). Finally, in most organoids derived from mice I and II, the Tp53 gene
had not recombined, whereas in all organoids from mice III and IV both Tp53 alleles had
recombined (Figure 1d; Figures S2d, S6 and S11).
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conditional alleles Apclox/lox, Tp53lox/lox, and LSL-KrasG12D. Blue boxes and orange triangles indicate exons and loxP sites, re-
spectively. (b) Four 3–4-month-old mice were injected with tamoxifen to initiate tumour development. Caecum and colon 
tumours were obtained for subsequent isolation of intestinal single cells. Normal tissue was also resected and used as 
control sample during sequencing analysis. Mouse IV developed metastatic lesions in the liver and metastatic tumour 
samples were also resected and sequenced. (c) Multi-region sampling of each mouse is illustrated by coloured labels. PT: 
primary tumours, MT: metastasis, O: tumour organoids. (d) Recombination events in organoids validated by PCR-based 
genotyping and by read depth analysis of sequencing data. Red, orange, and green colour indicate homozygous, hetero-
zygous and no recombination for Apclox/lox and Tp53lox/lox, respectively. For LSL-KrasG12D, red colour represents recombina-
tion of the conditional allele. 
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Single nucleotide substitutions (SNSs) were identified by comparing the exome se-
quencing data of single cell-derived tumour organoids to the corresponding data of bulk 
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tissue, except for mouse IV, for which we used the kidney, because its liver had metastatic 
lesions (Figures 1c and Figure S1c). For mouse IV, we also obtained exome sequencing 
data of primary and metastatic tumour tissue biopsies (Figures 1c and Figure S1c). 
One concern when analysing cancer sequencing data, in which few SNSs are ex-
pected per sample, is that a significant fraction of the identified variants may be germline 
polymorphisms and not somatic SNSs. This type of error will occur, when, due to low 
sequencing coverage, germline variants are identified in the sequences of the tumour 
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respectively. (b) Four 3–4-month-old mice were injected with tamoxifen to initiate tumour development. Caecum and colon
tumours were obtained for subsequent isolation of intestinal single cells. Normal tissue was also resected and used as control
sample during sequencing analysis. Mouse IV developed metastatic lesions in the liver and metastatic tumour samples
were also resected and sequenced. (c) Multi-region sampling of each mouse is illustrated by coloured labels. PT: primary
tumours, MT: metastasis, O: tumour organoids. (d) Recombination events in organoids validated by PCR-based genotyping
and by read depth analysis of sequencing data. Red, range, and green colour indicate homozygous, h terozygous and
no recombination for Apclox/lox and Tp53lox/lox, respectively. For LSL-KrasG12D, red colour represents recombination of the
conditional allele.
2.2. i l N leotide Substi utions—Prevalence
Single nucleotide substitutions (SNSs) were identified by comparing the ex me se-
quencing data f single cell-deriv d tumour organoids to the corresponding data of bulk
normal tissue fro the same mouse (Figure 1b). We us d th liver as the referenc normal
tissue, except for mouse IV, for which we used the kidney, because its liver had metastatic
lesions (Figure 1c and Figure S1c). For mous IV, we also obtained exome sequencing data
of primary and metastatic tumour tissue biopsi s (Fi ure 1c a d Figure S1c).
On concern when analysing ca cer sequencing data, n which few SNSs are expected
per sam le, is th t a significant fraction of the identified va iants may be germline polymor-
phisms and not somatic SNSs. This type of rror will occur, when, due to l w s quencing
coverage, germline variants are identified in the sequences of the tumour organoid, but
not in the sequences of the reference normal tissue. Given the very large number of non-
annotated germline variants in the mouse, such errors may be frequent. To minimise them,
we performed exome sequencing, which allowed us to have high sequencing coverage.
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In addition, we restricted the analysis to the protein-coding regions, because these are
well-annotated.
The exome sequencing data of 22 tumour organoids prepared from the four mice
revealed, in total, 206 somatic SNSs mapping to gene coding regions or splice sites (Data S1).
Of the 206 SNSs, 149 were missense, 3 nonsense, 44 synonymous and 10 were targeting
splice-sites (Figure 2a). We classified all the SNSs as passenger mutations, since none of
them targeted known oncogenes or tumour suppressor genes (as defined by ICGC/TCGA).
The average allele frequency of the SNSs in the organoids was approximately 50%
(Figure 2b). Considering that the organoids were derived from a single cell, these allele
frequencies are consistent with heterozygous mutations acquired in vivo. If the SNSs had
been acquired during tissue culture, they would not be present in all cells and would have
lower allele frequencies. By comparison, the allele frequencies of the SNSs in bulk tumour
tissue were lower than 50% (Figure 2b), reflecting intratumoural heterogeneity (see below)
and the presence of normal cells in bulk tumour tissue.
We next studied the spectrum of the identified SNSs. For mice I and II, tumour biopsies
that were a few mm apart from each other were used to prepare organoid cultures, and
one organoid culture was sequenced per tissue biopsy (Figure 1c). In these mice, no SNSs
were shared between the different organoids indicating that independent transformation
events took place in the different biopsies (Figure 2c). Indeed, mice I and II showed signs of
tumour development quite early after tamoxifen injection, consistent with the development
of many tumours in parallel.
For mouse III, a single tumour tissue biopsy was used to obtain organoid cultures,
two of which were subjected to exome sequencing (Figure 1c). Fourteen SNSs were shared
between the two organoids, and eight SNSs were private (two and six, respectively, in the
two organoids) (Figure 2c). At the very minimum, the private SNSs must have been
acquired after tumour development was initiated.
For mouse IV, two tumour tissue biopsies were harvested; three and four single
cell-derived organoid cultures were then sequenced from the two biopsies, respectively
(Figure 1c). Interestingly, all organoids shared four SNSs, whereas six of the seven organoids
shared an additional six SNSs (Figure 2c). Thus, the organoids derived from the two tumour
biopsies were related to each other. Given that the average frequency for all mutant alleles
was about 50% (Figure 2b), we infer that the SNSs were acquired in vivo. It is possible
that the four shared SNSs might have been acquired prior to neoplastic transformation.
In contrast, the private SNSs (29 in total; defined as SNSs found in only one of the seven
organoids) and the semi-private SNSs (12 in total; defined as SNSs found in more than
one, but not in all organoids) must have been acquired after neoplastic transformation
(Figure 2c).
Mouse IV was the only mouse that developed metastases to the liver. Histopathologi-
cal examination of primary tumours revealed the development of moderately differentiated
invasive adenocarcinoma of the colon, accompanied by mild to median desmoplastic and
mild inflammatory reaction of the stroma. The cancerous glands penetrated into the muscu-
laris propria. The metastatic cells also presented moderately differentiated adenocarcinoma
histology (Figure S1c). We attempted to establish organoids from the metastatic lesions,
but were unable to do so (Figure 1c and Figure S1b). However, we sequenced the exomes
of four distinct metastatic lesions (MT1–MT4) and also the exomes of the two primary
tumour biopsies (PT1, PT2), from which we had successfully obtained organoid cultures
(O1A-C and O2A-D). The four SNSs that were shared by all organoids were also present in
the primary and metastatic tumour biopsies. The majority of the semi-private SNSs were
present in at least one of the biopsies, whereas the majority of the private SNSs were absent
(Figure 2c). The two primary tumour biopsies had similar, although not identical SNSs
profiles, whereas three of the four metastatic lesions had distinct SNS profiles, indicating at
least three independent metastasis seeding events (Figure 2c).
Cancers 2021, 13, 1267 6 of 19




Figure 2. Types and allele frequencies of identified point mutations. (a) Number of single nucleotide substitutions (SNSs) 
within the protein-coding regions that were identified in the tumour organoids of all four mice. (b) Allele frequencies of 
coding and splicing somatic SNSs present in tumour organoids of mice I-IV and in primary and metastatic tumours of mouse 
IV. As expected, the average allele frequencies of the SNSs in the organoids were approximately 50% (red boxes), whereas in 
the primary and metastatic tumours (yellow and orange boxes, respectively) the SNS allele frequencies are lower. (c) Coding 
and splice site SNSs present in sequenced tissues and organoids. Red, blue, and green colours indicate nonsynonymous, 
synonymous and splice-site point mutations, respectively. For the primary and metastatic biopsies of mouse IV, SNSs with 
allele frequencies less than 20% or less than 10% are marked by boxes with decreased colour saturation. 
2.3. Single Nucleotide Substitutions—Link to Genotype and Distribution 
We next examined whether there was a correlation between the genotype of the organ-
oids and the number of SNSs acquired. The organoids from mice I and II, in which Apc was 
inactivated and mutant Kras was expressed, had accumulated fewer SNSs than the organ-
oids derived from mice III and IV, in which Tp53 was also inactivated (Figure 3a). Never-
theless, this difference might not be related to the genotype, because mice III and IV were 
sacrificed 20 and 25 weeks after tamoxifen administration, whereas mice I and II were sac-
rificed after two and ten weeks, respectively (Figure 1b). Thus, the number of SNSs in the 
four mice correlated well with the time over which the tumours developed (Figure 3b), im-
plying a similar rate of SNS acquisition over time in all mice. 
In a previous study, we had performed exome sequencing of single cell-derived or-
ganoids from Apcmin/+ mice; these organoids originated either from adenomatous polyp or 
normal intestine tissue. The average number of SNSs in the transformed Apcmin/min organ-
oids was very similar to the number of SNSs present in the organoids from mice I and II, 
which expressed mutant Kras, in addition to having inactivated Apc (Figure 3a). In 
i re . fi . ( ) r ti tit tions (S Ss)
it in t e r tei -coding regions that ere i entified in t e t r r a oids f all f r ice. ( ) llele fre e cies f
coding and splicing somatic SNSs present in tumour organoids of mice I-IV and in primary and metastatic tumours of
mouse IV. As expected, the average allele frequencies of the SNSs in the organoids were approximately 50% (red boxes),
whereas in the primary and metastatic tumours (yellow and orange boxes, respectively) the SNS allele frequencies are
lower. (c) Coding and splice site SNSs present in sequenced tissues and organoids. Red, blue, and green colours indicate
nonsynonymous, synonymous and splice-site point mutations, respectively. For the primary and metastatic biopsies of
mouse IV, SNSs with allele frequencies less than 20% or less than 10% are marked by boxes with decreased colour saturation.
2.3. Single Nucleotide Substitutions—Link to Genotype and Distribution
We next examined whether there was a correlation between the genotype of the
organoids and the number of SNSs acquired. The organoids from mice I and II, in which
Apc was inactivated and mutant Kras was expressed, had accumulated fewer SNSs than
the organoids derived from mice III and IV, in which Tp53 was also inactivated (Figure 3a).
Nevertheless, this difference might not be related to the genotype, because mice III and IV
were sacrificed 20 and 25 weeks after tamoxifen administration, whereas mice I and II were
sacrificed after two and ten weeks, respectively (Figure 1b). Thus, the number of SNSs in
the four mice correlated well with the time over which the tumours developed (Figure 3b),
implying a similar rate of SNS acquisition over time in all mice.
In a previous study, we had performed exome sequencing of single cell-derived
organoids from Apcmin/+ mice; these organoids originated either from adenomatous polyp
or normal intestine tissue. The average number of SNSs in the transformed Apcmin/min
organoids was very similar to the number of SNSs present in the organoids from mice I
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and II, which expressed mutant Kras, in addition to having inactivated Apc (Figure 3a).
In contrast, the organoids derived from non-transformed cells from the same mice had
significantly fewer SNSs than the transformed organoids (Figure 3a). These results suggest
that expression of mutant Kras did not have a significant effect on the rate by which SNSs
accumulate; on the other hand, transformed cells had a higher mutation rate than normal
cells. We note that colon cells that have as cancer-drivers only mutant Apc or only mutant
Apc and mutant Kras are generally precancerous in humans.
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To explore whether differences in SNS acquisition rates could be explained by dif-
ferences in proliferation rates, we calculated the cell doubling times in organoids with
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mutations in a single cancer-driver gene (Apc) and in organoids with mutations in three
cancer-driver genes (AKP) using the formula (1) described in the Section 4.6 of Materials
and Methods; the doubling times were 9.1 ± 0.4 and 8.2 ± 0.4 h, respectively (p = 0.08; not
statistically significant). The corresponding value for the Lgr5+ stem cells in organoids
derived from normal tissue is 12 h [22,51,52]. These values indicate that the large differ-
ence in SNSs present in non-transformed and transformed cells cannot be explained by
differences in proliferation rates.
An interesting feature of SNSs in human precancerous and cancerous lesions is that
they target more frequently large genes than small genes [29]. Mechanistically, one expla-
nation is that a slower progression of replication forks in cancer cells could result in the
central segments of large genes being replicated in mitosis by the break-induced replication
mechanism, which is error-prone [17,53–59]. We examined the distribution of somatic SNSs
according to gene size in the mouse tumour organoids and observed more SNSs per Mb
than expected in large genes (Figure 3c). This effect was statistically significant for mice II,
III and IV, but not for mouse I, which developed tumours rapidly.
2.4. Single Nucleotide Substitutions—Mutational Signature
SNSs in human cancers often target nucleotides in specific sequence contexts, which
are referred to as mutational signatures. Signature 1, which is the most prevalent mutational
signature in human cancers, describes the substitution of cytosines by thymines in the
context of NpCpG motifs [32,41]. This signature, although present in most cancers, exhibits
some tissue specificity and is particularly prevalent in precancerous lesions (adenomas)
and cancers of the colon [29]. We had previously observed this signature in organoids
derived from intestinal adenomas of Apcmin/+ mice [47]. In the current study, signature 1
was again the most prevalent signature (Figure S7a). The high prevalence of signature 1
became even more evident when the number of substitutions was normalised by the
frequency of the respective triplets in the genome (Figure 4a), since the NpCpG triplet is
quite underrepresented in the mouse genome (Table S1).
Interestingly, we also observed evidence for the presence of SNSs conforming to
signature 17 in the mouse organoids of our current study and of our previous study of
Apcmin/+ mice (Figure 4a and Figure S7a). Signature 17 is characterised by an elevated
number of T to G and T to C substitutions in the context of CpTpT trinucleotides. Its origin
is unknown, but it is particularly present in oesophageal, stomach and colon human
cancers [32,60–62].
To determine whether the mutational profiles observed in the mouse organoids were
similar to those present in human cancers, we reanalysed the published sequencing data of
36 human organoids derived from the tumours and normal tissues of three colorectal cancer
patients [48]. The SNSs within the protein-coding sequences revealed a strong signature 1
profile and a weak signature 17 profile, similar to what we observed in the mouse organoids
(compare Figure 4b and Figure S7b to Figure 4a and Figure S7a, respectively).
Since the human organoids were subjected to whole-genome sequencing, we were
able to examine more thoroughly their mutational signature profile. At the genome-wide
level, signature 1 was by far the most prevalent signature, followed by signature 17 in
patients 1 and 2 (Figure S8a). Further analysis of the SNSs conforming to these signatures
revealed a strong dependence on replication timing with more SNSs being present in late
S than in early S replication regions (Figure S8b). Within each replication timing domain,
the frequency of SNSs was similar in the protein-coding, intronic, and intergenic regions;
this was true for both signatures 1 and 17 (Figure S8c). Finally, we note that the SNSs
conforming to signature 1 and the C to T transitions in non-CpG contexts were the only
SNS types present in organoids derived from non-transformed cells (Figure S8a).
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2.5. Copy Number Alterations
To probe for copy number alterations (CNAs) in the mouse tumour organoids, we com-
pared the number of sequencing reads across the genome to the number of normal tissue
reads from the same mouse. For this type of analysis, whole-genome sequencing data are
superior to exome sequencing data; yet the high read coverage of our data allowed us to
identify copy number changes with a high degree of certainty (Figure S9).
For the organoids from mice I and II, the analysis did not reveal any convincing CNAs
(Figure 5). Small genomic regions with different ratios of the number of sequencing reads
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in the organoid and reference bulk normal tissue were observed, but similar differences
were observed when comparing the number of reads between different normal tissues.
Moreover, some of these differences were even shared between the organoids of mice I and
II, which strongly indicates that they were noise (Figure 5).
In contrast to mice I and II, several CNAs were evident in the organoids from mice
III and IV. The two organoids from mouse III shared CNAs on chromosomes 2, 6, and 16,
indicating that they were related (Figure 5). These two organoids also shared 14 SNSs
(Figure 2c). The seven organoids from mouse IV all shared loss of one copy of chr 13; five
of the seven organoids shared CNAs on chromosomes 9 and 11; and two of the seven
organoids shared a duplication of chr 6. Finally, organoid O1A had private CNAs on
chromosomes 5, 8, and 12 (Figure 5). Many of the CNAs observed in the organoids from
mouse IV were also evident in the primary and metastatic tumour biopsies. Interestingly,
metastatic lesion 1 had several CNAs that were not present in any of the organoids or
primary tumour samples; these CNAs included amplifications in chromosomes 9 and X
and deletions in chromosomes 1 and 9 (Figure 5).
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2.6. Evolution of Tumour Clones in Mouse IV
The availability of SNS and CNA data from several organoids and from primary and
metastatic tumour samples of mouse IV provided an opportunity to establish an order in
which these mutations were acquired during tumour evolution.
First, we plotted the allele frequencies of all the SNSs identified in the organoids and
tumours of mouse IV (Figure S10). In the organoids, most allele frequencies were close
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to 50%, consistent with one allele being mutated in a diploid region of the genome. For a
few SNSs, the allele frequencies deviated significantly from 50%, but all these SNSs were
located within genomic regions affected by CNAs. In the primary tumours, the SNS allele
frequencies ranged between less than 5% to about 30%: the four SNSs that were identified
in all organoids had allele frequencies of about 30%; whereas the allele frequencies of the
remaining SNSs were lower with the interesting exception of the SNSs that targeted the
Ociad2 and Vmn1r119 genes, which had allele frequencies close to 30%, even though they
were identified in only 3 out of the 7 organoids (Figure S10). In the metastatic lesions,
all SNSs had similar allele frequencies, consistent with each metastasis having been seeded
by a single cell or by a microcolony of genetically identical cells (Figure S10). Accordingly,
we included the metastatic lesions in the phylogenetic tree. We note that metastatic lesions
3 and 4 had exactly the same SNSs and CNAs (Figures 2c and 5).
To plot the phylogenetic tree, we started with the four SNSs (SNS-TRUNK) and the
deletion of one copy of chr 13 (CNA-TRUNK) that were present in all organoids and
metastatic lesions (Figure 6). Three branches could be projected from the trunk of the
phylogenetic tree. The first branch (B1) was formed by O2A and contained several private
mutations (SNS-B1); the second branch (B2) was formed by MT1 and contained private
CNAs affecting chromosomes 1, 9, and X (CNA-B2), as well as duplications of chr 6 and
chr 8; the third branch (B3) was formed by all other samples and contained a group of six
SNSs (SNS-B3). In regard to branch B2, we note that the duplications of chr 6 and chr 8
were also present in the O1A and MT2 samples, raising the possibility that the metastatic
lesion MT1 might not be monoclonal. Therefore, we attributed only the CNAs affecting
chromosomes 1, 9, and X to branch B2 (Figure 6b).
From branch B3, two branches originated; the first branch (B3A) encompassed O1A
and MT2 and was characterised by the presence of four SNSs (SNS-B3A), and duplications
of chromosomes 6, 8, and 12 (CNA-B3A). From this first branch, a sub-branch emerged
containing O1A and characterised by a group of six SNSs (SNS-B3Aa) and amplification
events in chr 5 (CNA-B3Aa). The second branch (B3B) emerging from branch B3, was
characterized by a SNS targeting Vnn2r99 (SNS-B3B), an amplification of part of chr 11 and
a deletion of part of chr 9 (CNA-B3B). In turn, two branches arose from branch B3B: branch
B3Ba, which was formed by O1B and was characterised by 7 private SNSs (SNS-B3Ba)
and duplication of chr 6 (CNA-B3Ba; we consider this to be an independent event from
the duplication of chr 6 observed in O1A and MT2) and branch B3Bb, which was formed
by O1C, O2B, O2C, O2D, and MT3/MT4 and was characterised by a SNS targeting the
Cntnap5b gene (SNS-B3Bb). From branch B3Bb, a branch (B3Bb1) containing O2B and O2C
emerged; in turn, this branch gave rise to two branches characterised by SNS-B3Bb1a and
SNS-B3Bb1b, respectively (Figure 6).
The phylogenetic tree encompassed all the SNSs and CNAs with the notable exception
of the SNSs targeting the Ociad2 and Vmn1r119 genes (Figure 6), as these SNSs could not be
incorporated in a way that made sense to us. What is evident is that tumour development
was associated with the parallel emergence of SNSs and CNAs.
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3. Discussion
Genomic instability is considered a major culprit of tumour development and emer-
gence of resistance to therapy. While the presence of genomic instability in cancer was
recognised at the beginning of the previous century, the advent of massive parallel se-
quencing has significantly advanced our understanding of the mechanisms leading to this
cancer hallmark [26].
Our study focused on two major types of genomic instability: chromosomal instability
and instability at the level of SNSs. The key question that we wanted to address was the
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extent to which the Apc, Kras and Tp53 genes, which are frequently implicated in colon
cancer development, contribute to the types of genomic instability mentioned above. As a
model system, we used tumour-prone mice that express mutant Kras and that inactivate
Apc, and Tp53. Single cell-derived organoids were examined to allow us to obtain a better
understanding of cancer development in the face of tumour heterogeneity. We compared
the current results to the results generated from our previous study, in which we performed
exome sequencing of organoids derived from precancerous lesions and matching normal
intestinal epithelium of Apcmin/+ mice [47].
The analysis of the data revealed a rather simple picture. The rate of accumulation of
SNSs was higher in the tumour-derived organoids than in the organoids derived from the
normal epithelium, but unaffected by the number of targeted cancer-driver genes. Thus,
the organoids with mutant Apc accumulated SNSs with the same rate as the organoids
with mutant Apc and mutant Kras and even the organoids with mutant Apc, mutant Kras,
and mutant Tp53. In contrast, CNAs were present almost exclusively in the organoids
harbouring mutant Tp53. Other studies had previously linked Tp53 mutations to the
induction of CNAs [49,63,64]. However, the observation that the rate of accumulation
of SNSs was independent of the number of mutant cancer-driver genes was unexpected.
We note that it remains to be determined if this is a feature of colon cancer or is more general.
As mentioned above, SNSs can exhibit specific patterns that are referred to as mu-
tational signatures [30,32,65]. Signature 1 is the most dominant signature and is char-
acterised by the presence of C to T substitutions in a CpG context; this signature arises
from spontaneous deamination of methylated cytosines to thymines [29,42,65]. It has
been proposed that signature 1 SNSs accumulate at a constant rate in both normal and
transformed cells [43–45]. Thus, their number would reflect the age of the organism. How-
ever, in our previous study of organoids derived from Apcmin/+ mice, the tumour-derived
organoids had a significantly higher number of CpG to TpG transitions than the organoids
derived from non-transformed cells [47]. Similarly, an analysis of the sequencing data
of organoids derived from three human colon cancer patients revealed more signature 1
SNSs in the tumour-derived organoids than the organoids derived from normal tissue [48]
and Figure S8. Nevertheless, signature 1 SNSs were present to a significant degree in the
normal tissue-derived organoids. In contrast, SNSs that do not conform to signature 1,
were present almost exclusively in the tumour-derived organoids (Figure S8). We conclude
that the mutagenic processes leading to signature 1 operate also in normal cells, albeit at a
lower level than in tumour cells, whereas the mutagenic processes that lead to the other
signatures are highly tumour-specific. Interestingly, all SNSs showed a dependence on
replication timing, with late S replicating regions being significantly more prone to muta-
genesis than the early S replicating regions. This dependency may explain why there is a
higher density of protein-coding sequences in the early S replicating regions of the genome.
The sequencing of single cell-derived organoids from the same tumour makes it
possible to construct a phylogenetic tree marking tumour development. In our study,
this was possible for mouse IV. Our analysis revealed a phylogenetic tree characterised
by the parallel emergence of SNSs and CNAs. In addition, analysis of metastatic lesions
demonstrated that apart from MT1, the rest were derived from a single cell or genetically
identical cells. In contrast, sequencing of the primary tumour tissue revealed a spectrum of
mutations typical of a heterogeneous population of cancer cells.
4. Materials and Methods
4.1. Mice
Three males (mI,mII,mIV) and one female(mIII) mice were kept on a 12 h light/dark
cycle in individually ventilated cages. The Apclox/lox mice [19,66], LSL-KrasG12D mice [67]
and Tp53lox/lox mice [68] were crossed to Cdx2CreERT2 mice (The Jackson Laboratory, Charles
River, L’Arbresle, France) [69] to obtain Apclox/lox; LSL-KrasG12D; Tp53lox/lox; Cdx2CreERT2
(AKP-Cdx2CreERT2) animals (Figure 1a,b). All experiments were authorised by the Can-
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ton of Vaud (license VD3396) and were performed according to accepted guidelines for
animal handling.
4.2. Histopathology of Tumour and Normal Caecum Tissues
Tissues were collected, washed in PBS, fixed in 4% PFA overnight, and processed for
dehydration and paraffin embedding according to standard procedures. Sections 7 µm
thick were cut using a rotary microtome (Hyrax M25 V2), dried at 60 ◦C for 1 h and stained
with hematoxylin-eosin (H&E) staining using standard protocols. Imaging was performed
on an upright microscope. H&E sections were evaluated independently by two certified
pathologists: Prof Vassilis Gorgoulis, Medical School, University of Athens, Greece; and
Prof. Mohammad Ilyas, School of Medicine, University of Nottingham, UK.
4.3. Genotyping
A small amount of tissue from each mouse was used for genotyping. Confirmation
of recombination events upon tamoxifen injection was assessed by genotyping the cor-
responding organoids that were selected for sequencing. For genotyping, the organoids
from one well of a 48-well plate were lysed in 200 µL lysis buffer supplemented with
150 µg Proteinase K and then incubated overnight at 55 ◦C. The lysates were diluted
10 times with water and subjected to PCR amplification using GoTaq Hot Start Polymerase
(M7423, Promega).
The following primers were used for genotyping: for the Cre allele: Cre_Fw (5′-
CACCAGCCAGCTATCAACTCG-3′) and Cre_Rev (5′-TTACATTGGTCCAGCCACCAG-
3′); for the Apclox allele: Apc_Fw (5′-GTTCTGTATCATGGAAAGATAGGTGGTC-3′) and
Apc_Rev1 (5′-CACTCAAAACGCTTTTGAGGGTTGATTC-3′) or Apc_Rev2 (5′-GAGTAC
GGGGTCTCTGTCTCAGTGAA-3′); for the Tp53lox allele: Tp53_Fw1 (5′-CACAAAAAA
CAGGTTAAACCCA-3′) or Tp53_Fw2 (5′-AAGGGG TATGAGGGACAAGG-3′) and Tp53_Rev
(5′-GAAGACAGAAAAGGGGAGGG-3′); for the LSL-KrasG12D allele: Kras_WT_Fw (5′-
TGTCTTTCCCCAGCACAGT-3′) or Kras_MUT_Fw (5′-CCATGGCTTGAGTAAGTCTGC-
3′) and Kras_common_rev (5′-CTGCATAGTACGCTATACCCTGT-3’). The PCR conditions
and DNA fragment sizes obtained are described in the Supplementary Information section.
4.4. Induction of Tumour Formation
Tamoxifen (Sigma), 3 mg/kg (or 30 mg/kg for mouse I), was administered either as a
single i.p. injection with sunflower oil (mouse II) or by gavage with peanut oil (mouse I,
mouse III, and mouse IV), when the mice were 10–14 weeks old. The mice were sacrificed
2 weeks (mouse I), 10 weeks (mouse II), 20 weeks (mouse III) or 25 weeks (mouse IV) after
tamoxifen administration.
4.5. Tissue Isolation, Organoid Culture, and Expansion
Intestinal tissue (colon or caecum) was isolated from AKP- Cdx2CreERT2 mice. Colonic
tumours were distinct and each was dissected and treated separately. For caecum tumours,
which effectively occupied nearly all the caecum space, the caecum was divided into several
parts and each part was considered as a separate tumour. For each tumour, the resected
tissue was cut into 2–3 mm wide cubes, that were separated by tissue also 2–3 mm wide.
The tumours of mouse III, isolated 20 weeks after tamoxifen administration, were small in
size and were not cut into separate pieces before processing (see Figure 1c and Figure S1b).
The tumour fragments were washed thoroughly in PBS-EDTA at 4 ◦C and then ho-
mogenised with a teflon pestle in 1.5 mL Eppendorf tubes. Tissue homogenates were
treated with Trypsin-EDTA for 3–4 min and quickly pipetted up and down, approximately
100–200 times, using 200 µL tips to disrupt any cell aggregates. After centrifugation, the pel-
lets were resuspended in ENR media, filtered through 70 µm cell strainers (BD Bioscience,
New Jersey, NJ, USA), and single cell suspensions were mixed with cold Matrigel® (Corning
Glendale, AZ, USA) and plated in 96-well plates. The tissue culture media (ENR) for these
organoids was based on DMEM/F12 with B27 and N2 (Life Technologies, Carlsbad, CA,
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USA) and contained, in addition, 10 mM HEPES, 100 units/mL penicillin and 100 µg/mL
streptomycin (Life Technologies), 2 mM L-Glutamine (Life Technologies) and 1.25 µM
N-Acetylcysteine (Sigma-Aldrich, Munich, Germany). The following growth factors were
also added: 50 ng/mL murine recombinant EGF (Life Technologies), R-Spondin1-Fc, and
Noggin-6xHis [70]. After the Matrigel solidified, ENR tissue culture media was added
on top. The suspensions of single cells were seeded at different cell concentrations to
obtain wells containing a single organoid. Selected organoids from each tumour piece were
then expanded to obtain enough material for DNA sequencing. For these organoids, the
medium was changed every 2 days and organoids were split every 3–4 days by mechanical
dissociation. Organoids were kept in culture as short as possible to obtain the necessary
amount of DNA for exome sequencing; on average, each organoid culture was split three
times. Around four to six 48-well plates full of organoids were harvested and the organoid
pellets were washed and frozen at −80 ◦C.
4.6. Measurement of Cell Doubling Times in Organoids
Organoids with one (Apc) or three (Apc;Kras;Tp53) mutant cancer-driver genes were
trypsinized and single cells were seeded. Three days later, organoids from each condition
were collected, trypsinized, and the number of cells was counted. Proliferation rate was
calculated by the formula:
duration(hoursa f terseeding) ∗ log(2)
log(averagenumbero f cellsperorganoidattimeo f harvest)− log(averagenumbero f cellsperorganoidattimeo f seeding) (1)
4.7. DNA Extraction and Exome Sequencing
Genomic DNA from the organoids was extracted and fragmented by sonication.
The resultant fragments (∼200 bp) were subjected to exome capture using the SureSelect
Mouse All Exon Kit (Agilent Technologies, Santa Clara, CA, USA) and paired-end libraries
were prepared and sequenced on an Illumina HiSeq 4000 platform.
4.8. Sequence Analysis
Sequencing reads were aligned on the mouse reference genome NCBI Build
GRCm38/mm10 using the Burrows-Wheeler Alignment tool v.0.7.17. Bam conversion,
sorting, removal of PCR duplicates, and indexing of the sequence alignment files was
conducted by SAMtools v.1.9. Somatic variant calling was performed by GATK v.4.11.0
using healthy tissue from the liver or kidney of the same mouse as matching normal sample.
False-positive calls were filtered out using a panel of normal samples constructed from all
normal tissues of 4 mice. Variants present in common mouse dbSnp142 were also discarded.
The mutational spectra of detected somatic SNSs were examined using the SomaticSigna-
ture v.2.20.0 R package for the analysis of all the 96 possible trinucleotide changes. CNA
events in bam files were analysed by VarScan2 v.2.4.3 using the recommended workflow.
To filter out somatic CNA events, we excluded CNAs that were present in the liver, kidney,
and spleen tissues of the mice from which the organoids were prepared. Segmentation was
applied by DNAcopy R package v.1.58.
4.9. SNS Signature Normalisation
The SNS signatures in mouse and human samples were normalised using the genomic
mouse and human sequences, respectively, downloaded from the NCBI RefSeq curated
dataset at the UCSC server (http://hgdownload.soe.ucsc.edu/goldenPath/ accessed on
4 October 2019). The coordinates of early-S, mid-S and late-S replicating regions of the
human genome were obtained from our previous analysis of U2OS cells [71].
5. Conclusions
An analysis of organoids derived from a mouse model of colorectal cancer has allowed
us to study the accumulation of SNSs and CNAs at the single cell level during tumour
evolution. The key conclusions are that the rate of accumulation of SNSs is higher in
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transformed than non-transformed cells and that it is unaffected by the number of cancer-
driver genes that are active in the tumour. Thus, tumours with mutant Apc accumulated
as many SNSs as tumours with mutant Apc, mutant Kras, and mutant Tp53. Signature
1 SNSs are the most prevalent in our model, but are also present to a lower degree in
normal cells. Moreover, late S replicating genomic regions are more prone to accumulate
SNSs. In contrast to SNSs, CNAs were observed only in cells with mutant Tp53. So far,
very few studies have been published sequencing single cell-derived tumour organoids.
Nevertheless, this approach has great potential to elucidate the mutagenic processes present
in cancer and, therefore, to contribute to our understanding of genomic instability.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6
694/13/6/1267/s1, Figure S1. Mouse breeding and preparation of organoids, Figure S2. Mouse
genotyping by PCR, Figure S3. Whole exome sequencing read depth of Apc genomic locus for mouse
I (a), mouse II (b), mouse III (c) and mouse IV(d), Figure S4. Whole exome sequencing read depth of
Kras genomic locus for mouse I (a), mouse II (b), mouse III (c) and mouse IV(d), Figure S5. Kras exon2
genotype detected by exome sequencing of mouse samples, Figure S6. Whole exome sequencing read
depth of Tp53 genomic locus for mouse I (a), mouse II (b), mouse III (c) and mouse IV(d), Figure S7.
Mutational signatures of somatic SNSs in tumour organoids, Figure S8. Mutational signatures of
somatic SNSs in human normal and tumour cell-derived organoids as a function of replication timing
and gene annotation, Figure S9. Examples of detected copy number alterations in mouse tumour
organoids, Figure S10. Allele frequencies of identified somatic SNSs, Figure S11. Original Images for
Figure S2, Table S1 and Data S1 attached as excel files.
Author Contributions: T.D.H., P.O.-M. and J.H. conceived the project and designed the experi-
ments, M.N., P.O.-M., A.K. and G.G.R. performed experiments, V.S.D. established the bioinformatics
pipelines and performed computational analysis with contributions from T.D.H., V.S.D., M.N.,
P.O.-M., J.H. and T.D.H. wrote the manuscript. All authors have read and agreed to the published
version of the manuscript.
Funding: This research was funded by the Carigest Foundation.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of
Canton de Vaud (license VD3396 and date of approval 8 January 2019).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The FASTQ files of mouse exome sequencing have been deposited at
the NCBI SRA database under the BioProject ID PRJNA675998.
Acknowledgments: The Apclox/lox mice were a kind gift of Tatiana Petrova, University of Lausanne,
Switzerland. We thank Michael R. Stratton for granting us access to the human colorectal cancer data
presented in the publication doi:10.1038/s41586-018-0024-3. We thank Mohammad Ilyas and Vassilis
Gorgoulis for histopathological examination.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Kinzler, K.W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159–170. [CrossRef]
2. Hamilton, S.R.; Powell, S.M.; Papadopoulos, N.; Smith, K.J.; Vogelstein, B.; Kinzler, K.W. Molecular Determinants of Dysplasia in
Colorectal Lesions. Cancer Res. 1994, 54, 5523–5526.
3. Vogelstein, B.; Kinzler, K.W. The multistep nature of cancer. Trends Genet. 1993, 9, 138–141. [CrossRef]
4. Powell, S.M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T.M.; Hamilton, S.R.; Thibodeau, S.N.; Vogelstein, B.; Kinzler, K.W. APC
mutations occur early during colorectal tumorigenesis. Nature 1992, 359, 235–237. [CrossRef] [PubMed]
5. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759–767. [CrossRef]
6. Vogelstein, B.; Fearon, E.R.; Hamilton, S.R.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Smits, A.M.M.; Bos, J.L. Genetic Alterations
during Colorectal-Tumor Development. N. Engl. J. Med. 1988, 319, 525–532. [CrossRef] [PubMed]
7. Roberts, D.M.; Pronobis, M.I.; Poulton, J.S.; Kane, E.G.; Peifer, M. Regulation of Wnt signaling by the tumor suppressor
adenomatous polyposis coli does not require the ability to enter the nucleus or a particular cytoplasmic localization. Mol. Biol.
Cell 2012, 23, 2041–2056. [CrossRef]
Cancers 2021, 13, 1267 17 of 19
8. Ghazvini, M.; Sonneveld, P.; Kremer, A.; Franken, P.; Sacchetti, A.; Atlasi, Y.; Roth, S.; Joosten, R.; Smits, R.; Fodde, R. Cancer
Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis. PLoS ONE 2013, 8, e73872. [CrossRef] [PubMed]
9. Schneikert, J.; Behrens, J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007, 56,
417–425. [CrossRef]
10. Stastna, M.; Janeckova, L.; Hrckulak, D.; Kriz, V.; Korinek, V. Human colorectal cancer from the perspective of mouse models.
Genes 2019, 10, 788. [CrossRef]
11. Tauriello, D.V.F.; Calon, A.; Lonardo, E.; Batlle, E. Determinants of metastatic competency in colorectal cancer. Mol. Oncol. 2017,
11, 97–119. [CrossRef]
12. Jackstadt, R.; Sansom, O.J. Mouse models of intestinal cancer. J. Pathol. 2016, 238, 141–151. [CrossRef] [PubMed]
13. Sottoriva, A.; Kang, H.; Ma, Z.; Graham, T.A.; Salomon, M.P.; Zhao, J.; Marjoram, P.; Siegmund, K.; Press, M.F.; Shibata, D.; et al.
A big bang model of human colorectal tumor growth. Nat. Genet. 2015, 47, 209–216. [CrossRef]
14. Rodrigues, N.R.; Rowan, A.; Smith, M.E.F.; Kerr, I.B.; Bodmer, W.F.; Gannon, J.V.; Lane, D.P. p53 mutations in colorectal cancer.
Proc. Natl. Acad. Sci. USA 1990, 87, 7555–7559. [CrossRef] [PubMed]
15. Weinberg, R.A. Oncogenes, Antioncogenes, and the Molecular Bases of Multistep Carcinogenesis. Cancer Res. 1989, 49, 3713–3721.
[PubMed]
16. Janssen, K.P.; Alberici, P.; Fsihi, H.; Gaspar, C.; Breukel, C.; Franken, P.; Rosty, C.; Abal, M.; El Marjou, F.; Smits, R.; et al. APC and
Oncogenic KRAS Are Synergistic in Enhancing Wnt Signaling in Intestinal Tumor Formation and Progression. Gastroenterology
2006, 131, 1096–1109. [CrossRef]
17. Halazonetis, T.D.; Gorgoulis, V.G.; Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 2008,
319, 1352–1355. [CrossRef]
18. Moser, A.R.; Pitot, H.C.; Dove, W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science
1990, 247, 322–324. [CrossRef]
19. Shibata, H.; Toyama, K.; Shioya, H.; Ito, M.; Hirota, M.; Hasegawa, S.; Matsumoto, H.; Takano, H.; Akiyama, T.; Toyoshima,
K.; et al. Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene. Science 1997, 278, 120–123.
[CrossRef] [PubMed]
20. Sansom, O.J.; Meniel, V.; Wilkins, J.A.; Cole, A.M.; Oien, K.A.; Marsh, V.; Jamieson, T.J.; Guerra, C.; Ashton, G.H.; Barbacid,
M.; et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.
Proc. Natl. Acad. Sci. USA 2006, 103, 14122–14127. [CrossRef]
21. Hung, K.E.; Maricevich, M.A.; Richard, L.G.; Chen, W.Y.; Richardson, M.P.; Kunin, A.; Bronson, R.T.; Mahmood, U.; Kucherlapati,
R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl.
Acad. Sci. USA 2010, 107, 1565–1570. [CrossRef]
22. Martin, E.S.; Belmont, P.J.; Sinnamon, M.J.; Richard, L.G.; Yuan, J.; Coffee, E.M.; Roper, J.; Lee, L.; Heidari, P.; Lunt, S.Y.; et al.
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res.
2013, 19, 2929–2940. [CrossRef]
23. Tetteh, P.W.; Kretzschmar, K.; Begthel, H.; Van Den Born, M.; Korving, J.; Morsink, F.; Farin, H.; Van Es, J.H.; Offerhaus, G.J.A.;
Clevers, H. Generation of an inducible colon-specific Cre enzyme mouse line for colon cancer research. Proc. Natl. Acad. Sci. USA
2016, 113, 11859–11864. [CrossRef]
24. Roper, J.; Tammela, T.; Cetinbas, N.M.; Akkad, A.; Roghanian, A.; Rickelt, S.; Almeqdadi, M.; Wu, K.; Oberli, M.A.; Sánchez-Rivera,
F.; et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat. Biotechnol. 2017,
35, 569–576. [CrossRef]
25. Hadjihannas, M.V.; Behrens, J. CIN by Wnt: Growth pathways, mitotic control and chromosomal instability in cancer. Cell Cycle
2006, 5, 2077–2081. [CrossRef] [PubMed]
26. Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010,
11, 220–228. [CrossRef]
27. Swanton, C. Intratumor heterogeneity: Evolution through space and time. Cancer Res. 2012, 72, 4875–4882. [CrossRef]
28. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey,
P.; et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl. J. Med. 2012, 366,
883–892. [CrossRef]
29. Nikolaev, S.I.; Sotiriou, S.K.; Pateras, I.S.; Santoni, F.; Sougioultzis, S.; Edgren, H.; Almusa, H.; Robyr, D.; Guipponi, M.; Saarela,
J.; et al. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer
Res. 2012, 72, 6279–6289. [CrossRef] [PubMed]
30. Alexandrov, L.B.; Kim, J.; Haradhvala, N.J.; Huang, M.N.; Tian Ng, A.W.; Wu, Y.; Boot, A.; Covington, K.R.; Gordenin, D.A.;
Bergstrom, E.N.; et al. The repertoire of mutational signatures in human cancer. Nature 2020, 578, 94–101. [CrossRef] [PubMed]
31. Van Hoeck, A.; Tjoonk, N.H.; Van Boxtel, R.; Cuppen, E. Portrait of a cancer: Mutational signature analyses for cancer diagnostics.
BMC Cancer 2019, 19, 457. [CrossRef]
32. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.;
Børresen-Dale, A.L.; et al. Signatures of mutational processes in human cancer. Nature 2013, 500, 415–421. [CrossRef]
33. Nik-Zainal, S.; Alexandrov, L.B.; Wedge, D.C.; Van Loo, P.; Greenman, C.D.; Raine, K.; Jones, D.; Hinton, J.; Marshall, J.; Stebbings,
L.A.; et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149, 979–993. [CrossRef] [PubMed]
Cancers 2021, 13, 1267 18 of 19
34. Kane, A.M.; Fennell, L.J.; Liu, C.; Borowsky, J.; McKeone, D.M.; Bond, C.E.; Kazakoff, S.; Patch, A.M.; Koufariotis, L.T.; Pearson,
J.; et al. Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF
mutant microsatellite stable colorectal cancer. Neoplasia 2020, 22, 120–128. [CrossRef]
35. Niknafs, N.; Zhong, Y.; Moral, J.A.; Zhang, L.; Shao, M.X.; Lo, A.; Makohon-Moore, A.; Iacobuzio-Donahue, C.A.; Karchin, R.
Characterization of genetic subclonal evolution in pancreatic cancer mouse models. Nat. Commun. 2019, 10, 5435. [CrossRef]
36. Connor, F.; Rayner, T.F.; Aitken, S.J.; Feig, C.; Lukk, M.; Santoyo-Lopez, J.; Odom, D.T. Mutational landscape of a chemically-
induced mouse model of liver cancer. J. Hepatol. 2018, 69, 840–850. [CrossRef]
37. Fantini, D.; Glaser, A.P.; Rimar, K.J.; Wang, Y.; Schipma, M.; Varghese, N.; Rademaker, A.; Behdad, A.; Yellapa, A.; Yu, Y.; et al.
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene
2018, 37, 1911–1925. [CrossRef] [PubMed]
38. Liu, H.; Murphy, C.J.; Karreth, F.A.; Emdal, K.B.; Yang, K.; White, F.M.; Elemento, O.; Toker, A.; Wulf, G.M.; Cantley, L.C.
Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer. Cancer Discov.
2018, 8, 354–369. [CrossRef]
39. Tauriello, D.V.F.; Palomo-Ponce, S.; Stork, D.; Berenguer-Llergo, A.; Badia-Ramentol, J.; Iglesias, M.; Sevillano, M.; Ibiza, S.;
Cañellas, A.; Hernando-Momblona, X.; et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
Nature 2018, 554, 538–543. [CrossRef] [PubMed]
40. Nassar, D.; Latil, M.; Boeckx, B.; Lambrechts, D.; Blanpain, C. Genomic landscape of carcinogen-induced and genetically induced
mouse skin squamous cell carcinoma. Nat. Med. 2015, 21, 946–954. [CrossRef]
41. Sjöblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; et al.
The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268–274. [CrossRef]
42. Lindahl, T. Instability and decay of the primary structure of DNA. Nature 1993, 362, 709–715. [CrossRef] [PubMed]
43. Tomasetti, C.; Vogelstein, B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell
divisions. Science 2015, 347, 78–81. [CrossRef]
44. Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A.; Kinzler, K.W. Cancer genome landscapes. Science 2013,
339, 1546–1558. [CrossRef] [PubMed]
45. Tomasetti, C.; Vogelstein, B.; Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate
prior to tumor initiation. Proc. Natl. Acad. Sci. USA 2013, 110, 1999–2004. [CrossRef]
46. McGranahan, N.; Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017, 168, 613–628.
[CrossRef]
47. Lugli, N.; Dionellis, V.S.; Ordóñez-Morán, P.; Kamileri, I.; Sotiriou, S.K.; Huelsken, J.; Halazonetis, T.D. Enhanced Rate of
Acquisition of Point Mutations in Mouse Intestinal Adenomas Compared to Normal Tissue. Cell Rep. 2017, 19, 2185–2192.
[CrossRef]
48. Roerink, S.F.; Sasaki, N.; Lee-Six, H.; Young, M.D.; Alexandrov, L.B.; Behjati, S.; Mitchell, T.J.; Grossmann, S.; Lightfoot, H.;
Egan, D.A.; et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature 2018, 556, 457–462. [CrossRef]
[PubMed]
49. Drost, J.; Van Jaarsveld, R.H.; Ponsioen, B.; Zimberlin, C.; Van Boxtel, R.; Buijs, A.; Sachs, N.; Overmeer, R.M.; Offerhaus, G.J.;
Begthel, H.; et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015, 521, 43–47. [CrossRef]
[PubMed]
50. Matano, M.; Date, S.; Shimokawa, M.; Takano, A.; Fujii, M.; Ohta, Y.; Watanabe, T.; Kanai, T.; Sato, T. Modeling colorectal cancer
using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 2015, 21, 256–262. [CrossRef] [PubMed]
51. Sato, T.; Vries, R.G.; Snippert, H.J.; Van De Wetering, M.; Barker, N.; Stange, D.E.; Van Es, J.H.; Abo, A.; Kujala, P.; Peters, P.J.; et al.
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459, 262–265. [CrossRef]
[PubMed]
52. Barker, N.; Van Es, J.H.; Kuipers, J.; Kujala, P.; Van Den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters,
P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449, 1003–1007. [CrossRef]
53. Elango, R.; Osia, B.; Harcy, V.; Malc, E.; Mieczkowski, P.A.; Roberts, S.A.; Malkova, A. Repair of base damage within break-induced
replication intermediates promotes kataegis associated with chromosome rearrangements. Nucleic Acids Res. 2019, 47, 9666–9684.
[CrossRef] [PubMed]
54. Costantino, L.; Sotiriou, S.K.; Rantala, J.K.; Magin, S.; Mladenov, E.; Helleday, T.; Haber, J.E.; Iliakis, G.; Kallioniemi, O.P.;
Halazonetis, T.D. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 2014,
343, 88–91. [CrossRef] [PubMed]
55. Deem, A.; Keszthelyi, A.; Blackgrove, T.; Vayl, A.; Coffey, B.; Mathur, R.; Chabes, A.; Malkova, A. Break-induced replication is
highly inaccurate. PLoS Biol. 2011, 9, e1000594. [CrossRef]
56. McAvoy, S.; Ganapathiraju, S.C.; Ducharme-Smith, A.L.; Pritchett, J.R.; Kosari, F.; Perez, D.S.; Zhu, Y.; James, C.D.; Smith, D.I.
Non-random inactivation of large common fragile site genes in different cancers. Cytogenet. Genome Res. 2007, 118, 260–269.
[CrossRef]
57. Helmrich, A.; Stout-Weider, K.; Hermann, K.; Schrock, E.; Heiden, T. Common fragile sites are conserved features of human and
mouse chromosomes and relate to large active genes. Genome Res. 2006, 16, 1222–1230. [CrossRef] [PubMed]
Cancers 2021, 13, 1267 19 of 19
58. Smith, D.I.; Zhu, Y.; McAvoy, S.; Kuhn, R. Common fragile sites, extremely large genes, neural development and cancer. Cancer
Lett. 2006, 232, 48–57. [CrossRef]
59. Gorgoulis, V.G.; Vassiliou, L.V.F.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; DiTullio, R.A.; Kastrinakis,
N.G.; Levy, B.; et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature
2005, 434, 907–913. [CrossRef] [PubMed]
60. Secrier, M.; Li, X.; De Silva, N.; Eldridge, M.D.; Contino, G.; Bornschein, J.; Macrae, S.; Grehan, N.; O’Donovan, M.; Miremadi,
A.; et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Nat. Genet. 2016, 48, 1131–1141. [CrossRef]
61. Dulak, A.M.; Stojanov, P.; Peng, S.; Lawrence, M.S.; Fox, C.; Stewart, C.; Bandla, S.; Imamura, Y.; Schumacher, S.E.; Shefler,
E.; et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational
complexity. Nat. Genet. 2013, 45, 478–486. [CrossRef] [PubMed]
62. Christensen, S.; Van der Roest, B.; Besselink, N.; Janssen, R.; Boymans, S.; Martens, J.W.M.; Yaspo, M.L.; Priestley, P.; Kuijk, E.;
Cuppen, E.; et al. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat. Commun. 2019, 10, 4571.
[CrossRef] [PubMed]
63. Donehower, L.A.; Soussi, T.; Korkut, A.; Liu, Y.; Schultz, A.; Cardenas, M.; Li, X.; Babur, O.; Hsu, T.K.; Lichtarge, O.; et al.
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019, 28, 1370–1384.e5.
[CrossRef] [PubMed]
64. Eischen, C.M. Genome stability requires p53. Cold Spring Harb. Perspect. Med. 2016, 6, a026096. [CrossRef]
65. Helleday, T.; Eshtad, S.; Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 2014, 15,
585–598. [CrossRef]
66. Sansom, O.J.; Reed, K.R.; Hayes, A.J.; Ireland, H.; Brinkmann, H.; Newton, I.P.; Batlle, E.; Simon-Assmann, P.; Clevers, H.; Nathke,
I.S.; et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 2004, 18, 1385–1390.
[CrossRef]
67. Jackson, E.L.; Willis, N.; Mercer, K.; Bronson, R.T.; Crowley, D.; Montoya, R.; Jacks, T.; Tuveson, D.A. Analysis of lung tumor
initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15, 3243–3248. [CrossRef]
68. Marino, S.; Vooijs, M.; Van Der Gulden, H.; Jonkers, J.; Berns, A. Induction of medulloblastomas in p53-null mutant mice by
somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000, 14, 994–1004.
69. Feng, Y.; Sentani, K.; Wiese, A.; Sands, E.; Green, M.; Bommer, G.T.; Cho, K.R.; Fearon, E.R. Sox9 induction, ectopic paneth cells,
and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. Am.
J. Pathol. 2013, 183, 493–503. [CrossRef]
70. Ordóñez-Morán, P.; Dafflon, C.; Imajo, M.; Nishida, E.; Huelsken, J. HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt
Signaling in Colorectal Cancer. Cancer Cell 2015, 28, 815–829. [CrossRef]
71. Macheret, M.; Halazonetis, T.D. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress.
Nature 2018, 555, 112–116. [CrossRef] [PubMed]
